Inhibikase Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Acquisition of CorHepta - Schedule of Fair Value of Consideration Transferred (Details)

v3.25.1

Acquisition of CorHepta - Schedule of Fair Value of Consideration Transferred (Details) - USD ($)		3 Months Ended
	Feb. 21, 2025	Mar. 31, 2025
Fair Value, Recurring [Member]
Business Acquisition [Line Items]
Fair value of consideration		$ 7,338,719
Series of Individually Immaterial Asset Acquisitions \| Fair Value, Recurring [Member]
Business Acquisition [Line Items]
Contingent consideration	$ 4,435,443
CorHepta Pharmaceuticals [Member]
Business Acquisition [Line Items]
Fair value of consideration		$ 7.4
CorHepta Pharmaceuticals [Member] \| Fair Value, Recurring [Member]
Business Acquisition [Line Items]
Fair value of fully vested shares	2,464,652
Transaction costs incurred by the Company	438,624
Fair value of consideration	$ 7,338,719
CorHepta Pharmaceuticals [Member] \| Common Stock
Business Acquisition [Line Items]
Shares vested	829,849	829,849
Shares representing contingent consideration	2,489,030	1,493,415
Share Price at Closing		$ 2.97

- Definition

Fair Value of Fully Vested Shares

+ References

No definition available.

+ Details

Name:	ikt_FairValueOfFullyVestedShares
Namespace Prefix:	ikt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Shares Representing Contingent Consideration

+ References

No definition available.

+ Details

Name:	ikt_SharesRepresentingContingentConsideration
Namespace Prefix:	ikt_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Shares Vested on Acquisition

+ References

No definition available.

+ Details

Name:	ikt_SharesVestedOnAcquisition
Namespace Prefix:	ikt_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 8
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479637/805-30-30-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 7
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479637/805-30-30-7

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ikt_CorHeptaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: